biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC

VANCOUVER, BRITISH COLUMBIA, April 21st, 2016: biOasis Technologies Inc. (TSX.V: BTI)(OTCQB: BIOAF)(the “Company”) announces that it has entered into a License Agreement to collaborate with Astellas Research Institute of America LLC (“Astellas”). The terms of the agreement, for competitive reasons, remain confidential, as do the specific therapeutic targets and work programs. The companies intend to collaborate on the internalization and assessment of the biOasis Transcend technology.

“We at biOasis are looking forward to working with Astellas’s US Research Institute in the pursuit of taking Transcend commercially forward,” says Rob Hutchison, CEO, biOasis. “Over the coming months, biOasis and Astellas will work to outline specific programs and to commence the execution of them in a timely manner.”

About biOasis

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis’ proprietary brain delivery platform, the Company is focused on enabling Pharmaceutical companies to deliver their brain-targeted therapeutics. By doing so, new therapeutics are created that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.

http://www.astellas.ca/research/